374 related articles for article (PubMed ID: 26530370)
1. CA 19-9: Biochemical and Clinical Aspects.
Scarà S; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():247-60. PubMed ID: 26530370
[TBL] [Abstract][Full Text] [Related]
2. Role of tumour markers, cytogenetics.
Lamerz R
Ann Oncol; 1999; 10 Suppl 4():145-9. PubMed ID: 10436809
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the diagnostic value of serum tumor markers, and fecal k-ras and p53 gene mutations for pancreatic cancer.
Wu X; Lu XH; Xu T; Qian JM; Zhao P; Guo XZ; Yang XO; Jiang WJ
Chin J Dig Dis; 2006; 7(3):170-4. PubMed ID: 16808798
[TBL] [Abstract][Full Text] [Related]
4. New observations on the utility of CA19-9 as a biomarker in Lewis negative patients with pancreatic cancer.
Luo G; Fan Z; Cheng H; Jin K; Guo M; Lu Y; Yang C; Fan K; Huang Q; Long J; Liu L; Xu J; Lu R; Ni Q; Warshaw AL; Liu C; Yu X
Pancreatology; 2018 Dec; 18(8):971-976. PubMed ID: 30131287
[TBL] [Abstract][Full Text] [Related]
5. Preoperative CEA and CA 19-9 are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study.
Distler M; Pilarsky E; Kersting S; Grützmann R
Int J Surg; 2013; 11(10):1067-72. PubMed ID: 24161419
[TBL] [Abstract][Full Text] [Related]
6. CA 19-9: handle with care.
Galli C; Basso D; Plebani M
Clin Chem Lab Med; 2013 Jul; 51(7):1369-83. PubMed ID: 23370912
[TBL] [Abstract][Full Text] [Related]
7. [Is the carbohydrate antigen Ca 19.9 useful in the diagnosis of pancreatic carcinoma?].
Santander C; Jiménez I; Martín E; Melón A; Pajares JM
Rev Esp Enferm Dig; 1994 Nov; 86(5):819-21. PubMed ID: 7848693
[TBL] [Abstract][Full Text] [Related]
8. Optimize CA19-9 in detecting pancreatic cancer by Lewis and Secretor genotyping.
Luo G; Guo M; Jin K; Liu Z; Liu C; Cheng H; Lu Y; Long J; Liu L; Xu J; Ni Q; Yu X
Pancreatology; 2016; 16(6):1057-1062. PubMed ID: 27692554
[TBL] [Abstract][Full Text] [Related]
9. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
10. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer.
Jiang XT; Tao HQ; Zou SC
Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):464-8. PubMed ID: 15313690
[TBL] [Abstract][Full Text] [Related]
11. Serum APRIL, a potential tumor marker in pancreatic cancer.
Wang F; Chen L; Ding W; Wang G; Wu Y; Wang J; Luo L; Cong H; Wang Y; Ju S; Shao J; Wang H
Clin Chem Lab Med; 2011 Oct; 49(10):1715-9. PubMed ID: 21612541
[TBL] [Abstract][Full Text] [Related]
12. Combined serum CA19-9 and miR-27a-3p in peripheral blood mononuclear cells to diagnose pancreatic cancer.
Wang WS; Liu LX; Li GP; Chen Y; Li CY; Jin DY; Wang XL
Cancer Prev Res (Phila); 2013 Apr; 6(4):331-8. PubMed ID: 23430754
[TBL] [Abstract][Full Text] [Related]
13. CEACAM1, a novel serum biomarker for pancreatic cancer.
Simeone DM; Ji B; Banerjee M; Arumugam T; Li D; Anderson MA; Bamberger AM; Greenson J; Brand RE; Ramachandran V; Logsdon CD
Pancreas; 2007 May; 34(4):436-43. PubMed ID: 17446843
[TBL] [Abstract][Full Text] [Related]
14. Increase diagnostic accuracy in differentiating focal type autoimmune pancreatitis from pancreatic cancer with combined serum IgG4 and CA19-9 levels.
Chang MC; Liang PC; Jan S; Yang CY; Tien YW; Wei SC; Wong JM; Chang YT
Pancreatology; 2014; 14(5):366-72. PubMed ID: 25278306
[TBL] [Abstract][Full Text] [Related]
15. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma.
Pasquali C; Sperti C; D'Andrea AA; Costantino V; Filipponi C; Pedrazzoli S
Ital J Gastroenterol; 1994 May; 26(4):169-73. PubMed ID: 7949259
[TBL] [Abstract][Full Text] [Related]
16. Predicting factors for unresectability in patients with pancreatic ductal adenocarcinoma.
Okada K; Kawai M; Tani M; Hirono S; Miyazawa M; Shimizu A; Kitahata Y; Yamaue H
J Hepatobiliary Pancreat Sci; 2014 Sep; 21(9):648-53. PubMed ID: 24764208
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
18. [Tumor markers for pancreatic and biliary tract cancer].
Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
[TBL] [Abstract][Full Text] [Related]
19. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer.
Goonetilleke KS; Siriwardena AK
Eur J Surg Oncol; 2007 Apr; 33(3):266-70. PubMed ID: 17097848
[TBL] [Abstract][Full Text] [Related]
20. Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases.
Ozkan H; Akar T; Köklü S; Coban S
Pancreatology; 2006; 6(4):268-72. PubMed ID: 16636598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]